VIP 10mg

Research

This document presents a technical and academic analysis of Vasoactive Intestinal Peptide (VIP), a 28-amino-acid endogenous neuropeptide with pleiotropic functions in the immune, neurological, and metabolic systems.

1.Scientific Research on VIP (Vasoactive Intestinal Peptide)

VIP is a member of the secretin/glucagon superfamily, originally isolated from the gastrointestinal tract but later identified as a ubiquitous neurotransmitter and neuromodulator. It is produced by central and peripheral neurons, as well as immune cells (T and B lymphocytes). Due to its widespread distribution, VIP operates at the interface between the neuroendocrine and immune systems and is a major focus of research in autoimmune, inflammatory, and neurodegenerative diseases.

2. Mechanism of Action and Inhibition

VIP exerts its functions by binding to two high-affinity G protein-coupled receptors (GPCRs), $VPAC_1$ and $VPAC_2$, as well as a lower-affinity receptor, PAC1.

• Cellular Signaling: Binding of VIP to $VPAC_1$ or $VPAC_2$ activates adenylate cyclase, resulting in increased intracellular cyclic adenosine monophosphate (cAMP) levels and activation of protein kinase A (PKA).
• Immune Modulation: VIP inhibits the production of pro-inflammatory cytokines ($TNF$-$\alpha$, $IL$-$6$, $IL$-$12$) and stimulates the production of anti-inflammatory cytokines such as $IL$-$10$. It also promotes the differentiation of naïve T cells into regulatory T cells (Tregs).
• Inhibition: VIP activity is naturally limited by enzymes such as dipeptidyl peptidase-IV (DPP-IV) and other neutral endopeptidases that cleave the peptide, reducing its bioavailability. Research utilizes specific antagonists such as $[D\text{-}p\text{-}Cl\text{-}Phe^6, Leu^{17}]\text{-}VIP$ to selectively block its receptors in experimental models.

3. Investigated Metabolic Impacts

VIP plays a crucial role in regulating energy metabolism and glucose homeostasis:

• Endocrine Pancreas: VIP stimulates glucose-dependent insulin secretion and glucagon release, acting as a fine regulator of pancreatic islet function.
• Hepatic Glycogenolysis: Promotes glycogen breakdown in the liver to supply glucose during periods of increased energy demand.
• Circadian Rhythms: VIP is a key neurotransmitter in the suprachiasmatic nucleus (SCN) of the hypothalamus, essential for synchronizing metabolic circadian rhythms and the sleep-wake cycle.
• Lipolysis: In adipose tissue, VIP can stimulate lipolysis via activation of the cAMP/PKA pathway.

4. Investigation in Oncological Models

VIP’s role in oncology is dual and context-dependent, making it a complex research target:

• Tumor Proliferation: Many solid tumors (breast, prostate, lung, and colon) overexpress $VPAC_1$ receptors. VIP may act as an autocrine and paracrine growth factor, promoting malignant cell survival and proliferation.
• Angiogenesis: The peptide stimulates the expression of Vascular Endothelial Growth Factor (VEGF), facilitating tumor neovascularization.
• Bioimaging Applications: Due to the high density of $VPAC_1$ receptors in cancer cells, radiolabeled VIP analogs (e.g., with Technetium-99m or Copper-64) are being investigated as high-precision diagnostic tools for metastasis localization.
• VIPomas: Neuroendocrine tumors that secrete VIP (Verner-Morrison syndrome) serve as the classical clinical model for studying systemic overexposure to this peptide (watery diarrhea, hypokalemia, and achlorhydria).

5. Pharmacokinetic Considerations in Research

• Plasma Half-life: Extremely short, estimated at 1 to 2 minutes in humans, due to rapid proteolytic degradation and hepatic/renal clearance.
• Stability: To overcome metabolic instability, pharmacological research focuses on developing stabilized analogs, PEGylated variants, or nanoparticle encapsulation.
• Route of Administration: In studies targeting pulmonary diseases (such as sarcoidosis or pulmonary hypertension), inhalation is often preferred to minimize systemic side effects (e.g., hypotension) and maximize local concentration.

6. Other Relevant Research Associations

• Inflammatory Lung Diseases: VIP is under clinical investigation for the treatment of sarcoidosis and COPD due to its bronchodilatory and anti-inflammatory properties.
• Neuroprotection: In models of Parkinson’s disease and Multiple Sclerosis, VIP has demonstrated neuroprotective effects and reduction of microglia-mediated neuroinflammation.
• Vasodilatory Effect: It is one of the most potent known vasodilators, reducing systemic and pulmonary vascular resistance.

7. Final Considerations

VIP is a fundamental molecule for understanding the neuroimmune network. For researchers, the main challenge lies in dissociating its potent anti-inflammatory and neuroprotective therapeutic effects from its proliferative potential in oncological contexts and its pharmacokinetic instability. The future of VIP research points toward the development of selective receptor agonists ($VPAC_2$ vs $VPAC_1$) and targeted delivery systems to minimize unwanted vasodilatory effects.

8. References

• Gonzalez-Rey, E., Chorny, A., & Delgado, M. (2007). Vasoactive intestinal peptide: an extra-pancreatic master of glucose homeostasis. Trends in Molecular Medicine, 13(2). https://doi.org/10.1016/j.molmed.2006.12.002
• Moody, T. W., Nuche-Berenguer, B., & Jensen, R. T. (2016). Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 23(1). https://doi.org/10.1097/MED.0000000000000218
• Prasse, A., Zissel, G., Lützen, N., et al. (2010). Inhaled vasoactive intestinal peptide therapy in sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 182(4). https://doi.org/10.1164/rccm.200909-1440OC
• Myong, S., Nguyen, A., & Challa, S. (2024). Biological functions and therapeutic potential of NAD+ metabolism in gynecological cancers. Cancers, 16. https://doi.org/10.3390/cancers16173085